During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

If successfully developed, the candidate could greatly improve the quality of life for cancer patients suffering from EGFRI-induced skin toxicities. Year to date, shares of HOTH have lost 12.5% ...

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, ...

The toxicity of lung cancer treatment has traditionally been discussed in terms of physical symptoms, but there is a growing focus on financial toxicity, time toxicity, and other effects on well-being ...

What should you do if your dog eats a clove of garlic? Here are the toxic foods every owner should know and what to do if ...

Shares of Hoth Therapeutics HOTH surged 81.4% on Sept. 5, after the company announced positive data from the treatment of the ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...